Pancreatic Cancer Research

ResearcherInstitut d'Investigació Biomédica de BellvitgeActive in the last 2 years

Berta Laquente

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2477-1673; OpenAlex author ID A5029418459. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Co-author DOI 10.1097/coc.0000000000001253↗
  2. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2023.102027↗
  3. Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospect… Co-author DOI 10.1097/md.0000000000032126↗
  4. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Co-author DOI 10.1136/jitc-2021-003254↗
  5. Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice. Co-author DOI 10.1186/s12904-020-00610-4↗
  6. Management and supportive treatment of frail patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.jgo.2018.06.005↗
  7. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD… Co-author DOI 10.1007/s00280-018-3682-9↗
  8. Initial Experience in the Treatment of "Borderline Resectable" Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ciresp.2017.07.008↗
  9. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. Co-author DOI 10.1186/s12885-017-3131-x↗
  10. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Co-author DOI 10.1007/s12094-016-1586-x↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juli Busquets · 4 shared papers, 2017–2026 · strength 0.71
  2. Teresa Mercade Macarulla · 4 shared papers, 2016–2026 · strength 0.50
  3. Juan Fabregat · 3 shared papers, 2017–2024 · strength 0.46
  4. Lluís Secanella · 3 shared papers, 2017–2024 · strength 0.46
  5. Rafael Álvarez-Gallego · 2 shared papers, 2021–2026 · strength 0.35
  6. Florian Castet · 1 shared paper, 2026 · strength 0.25
  7. Yolanda Quijano · 1 shared paper, 2026 · strength 0.25
  8. Emilio Vicente · 1 shared paper, 2026 · strength 0.25
  9. Antonio Cubillo · 1 shared paper, 2026 · strength 0.25
  10. Manuel M. Hidalgo · 2 shared papers, 2019–2021 · strength 0.19
  11. Adelaida Garcia-Velasco · 2 shared papers, 2019–2020 · strength 0.19
  12. Helena Verdaguer · 2 shared papers, 2017–2020 · strength 0.16
  13. Marta Martín-Richard · 2 shared papers, 2018–2020 · strength 0.15
  14. Laura Visa · 2 shared papers, 2018–2020 · strength 0.15
  15. Joan Maurel · 2 shared papers, 2016–2018 · strength 0.12
  16. María Victoria Maliandi · 1 shared paper, 2021 · strength 0.10
  17. Miriam Bazán‐Peregrino · 1 shared paper, 2021 · strength 0.10
  18. Rocio García‐Carbonero · 1 shared paper, 2021 · strength 0.10
  19. Gabriel Capellá · 1 shared paper, 2021 · strength 0.10
  20. Joan B. Gornals · 1 shared paper, 2021 · strength 0.10
  21. Rafael Álvarez · 1 shared paper, 2019 · strength 0.10
  22. Alfredo Carrato · 1 shared paper, 2019 · strength 0.10
  23. Carles Pericay · 1 shared paper, 2020 · strength 0.09
  24. Emilio Ramos · 1 shared paper, 2017 · strength 0.06
  25. Laureano Fernández‐Cruz · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.